Abstract: The present invention concerns compositions and methods of extracting infectious pathogens from a volume of blood. In one embodiment, the method includes the steps of creating a fibrin aggregate confining the pathogens and introducing a fibrin lysis reagent to expose the pathogens for analysis. The present invention also concerns materials and methods for removing aurintricarboxylic acid (ATA) from a sample.
Abstract: The present invention relates to a composition comprising a stable aqueous dispersion of polymer particles, an oxidoreductase, and a cofactor for the oxidoreductase and a method for its preparation. The invention is useful for converting certain classes of VOCs to non-VOCs.
Type:
Grant
Filed:
May 13, 2013
Date of Patent:
December 16, 2014
Assignee:
Rohm and Haas Company
Inventors:
David L. Frattarelli, Kathleen Rising Manna, James Charles Bohling, Selvanathan Arumugam
Abstract: A composite comprising a stem cell; a biodegradable layer, which can provide an environment for the stem cell to grow and to differentiate, and; a N-isopropylacrylamide (NIPAAm), which can polymerize with the biodegradable layer and possess the temperature-responsive character for easy stripping. The present invention further provides a method for treating a patient with a skin defect, consisting of (a) providing said patient with a composite consisting of a N-isopropylacrylamide (NIPAAm) layer polymerized with a biodegradable layer containing gelatin and a layer of polypropylene (PP) non-woven, wherein a bone marrow derived mononuclear cell with CD45 negative and glycophorin A negative is cultivating on the biodegradable layer; (b) covering said composite on the skin defect of the patient; and (c) treating the composite with water below 25° C. to strip off the layer of polypropylene (PP) non-woven.
Type:
Grant
Filed:
April 17, 2013
Date of Patent:
December 9, 2014
Assignee:
Taipei Veterans General Hospital
Inventors:
Shih-Hwa Chiou, Cherng-Kang Perng, Han-Tzo Lin, Yi-Ping Yang
Abstract: A method for forming a nerve graft includes the following steps. A carbon nanotube structure is provided. A hydrophilic layer is formed on a surface of the carbon nanotube structure. The hydrophilic layer is polarized to form a polar surface on the hydrophilic layer. A number of neurons are formed on the polar surface of the hydrophilic layer to form a nerve network. The neurons connect with each other.
Type:
Grant
Filed:
January 13, 2012
Date of Patent:
December 2, 2014
Assignees:
Tsinghua University, Hon Hai Precision Industry Co., Ltd.
Abstract: The present invention discloses a process for producing purple-blue natural pigment containing violacein and its derivative (deoxyviolacein) using Chromobacterium sp. NIIST-CKK-01 (MTCC 5522, NCIM 5341; Genbank Accession No. FJ982784). The method comprises the steps of maintaining and growing the bacterium in a specific medium under defined conditions of pH, temperature and agitation. At the end of incubation, pigment and biomass is separated from the culture broth, pigment is recovered from the biomass through solvent extraction and finally pigment is concentrated by drying.
Type:
Grant
Filed:
March 10, 2011
Date of Patent:
November 11, 2014
Assignee:
Council of Scientific & Industrial Research
Abstract: A method of producing saccharides containing glucose as the major constituent by degrading at least one selected from the group consisting of cellulose and hemicellulose with a cellulose saccharifying enzyme is provided. The method includes the steps of: mixing a cellulose material and a solution containing cellulose saccharifying enzyme to prepare a mixture; and saccharifying the cellulose material with the saccharifying enzyme. A gross energy density Y (W/m3) subjected to the mixture and a substrate concentration X (w/v%) of the cellulose material to the enzyme solution satisfy a formula (1) below during the step of saccharifying. Y??0.0125X2+1.195X+23.
Abstract: Described is a new stand-alone diguanylate cyclase polypeptide having a GGDEF motif and a mutated I-site that does not bind c-di-GMP. We demonstrate that the production yield of c-di-GMP and analogues was significantly increased by mutation of a conserved residue in the putative regulatory I-site.
Abstract: A microfluidic apparatus, method, and associated applications utilize and apply to a formalin-fixed paraffin-embedded (FFPE) tissue sample and performing a liquid-liquid extraction to remove the paraffin from the tissue sample prior to a nucleic acid purification step. A microfluidic device includes a dedicated liquid-liquid extraction process vessel, a nucleic acid purification process component, and a nucleic acid amplification reactor. A liquid-liquid extraction and nucleic acid purification kit includes a microfluidic device capable of performing both a liquid-liquid extraction process and a nucleic acid purification process, including a dedicated liquid-liquid extraction process vessel, an immiscible liquid or a precursor phase thereof disposed in the vessel, a nucleic acid purification process component, a nucleic acid amplification reactor fluidically, and a supply of reagents suitable to enable the liquid-liquid extraction process and the nucleic acid purification process.
Abstract: According to embodiments, a method of producing insulin-producing tissues (IPTs) by culturing comprises: preparing non-endocrinal epithelial cells (NEECs) and vascular endothelial cells (VECs), which have been isolated or originated from postnatal pancreata, preferably by capturing of NEECs by collagen; culturing in vitro the NEECs and the VECs at least partly separately from each other; and then generating in vitro a tissue complex (IPTs) that contains both the NEECs and the VECs. In another embodiment, the native islet cells are seeded on a monolayer of VECs that have preferably been separately cultured and purified. In a further embodiment, a method of enriching NEECs comprises: culturing NEECs adhering to a container or substrate; removing NEECs by treating with a tissue-dissociation enzyme to leave left-over cells (LOCs) still attached on the container or substrate; and culturing NEECs in a medium conditioned by, or in the presence of the LOCs.
Type:
Grant
Filed:
March 15, 2011
Date of Patent:
October 7, 2014
Assignee:
Kyoto University
Inventors:
Jun Kanamune, Yasuhiro Iwanaga, Shinji Uemoto, Yoshiya Kawaguchi
Abstract: The present invention concerns compositions and methods of extracting infectious pathogens from a volume of blood. In one embodiment, the method includes the steps of creating a fibrin aggregate confining the pathogens and introducing a fibrin lysis reagent to expose the pathogens for analysis. The present invention also concerns materials and methods for removing aurintricarboxylic acid (ATA) from a sample.
Type:
Grant
Filed:
December 21, 2012
Date of Patent:
August 26, 2014
Assignee:
University of South Florida
Inventors:
Matt Ewert, Philip Amuso, Andrew Cannons
Abstract: The present invention concerns compositions and methods of extracting infectious pathogens from a volume of blood. In one embodiment, the method includes the steps of creating a fibrin aggregate confining the pathogens and introducing a fibrin lysis reagent to expose the pathogens for analysis. The present invention also concerns materials and methods for removing aurintricarboxylic acid (ATA) from a sample.
Type:
Grant
Filed:
January 4, 2013
Date of Patent:
July 22, 2014
Assignee:
University of South Florida
Inventors:
Matt Ewert, Philip Amuso, Andrew Cannons
Abstract: The present invention concerns compositions and methods of extracting infectious pathogens from a volume of blood. In one embodiment, the method includes the steps of creating a fibrin aggregate confining the pathogens and introducing a fibrin lysis reagent to expose the pathogens for analysis. The present invention also concerns materials and methods for removing aurintricarboxylic acid (ATA) from a sample.
Abstract: An energy independent dry corn fractionation ethanol production system which utilizes at least one product of a dry corn fractionation process as fuel to generate power for the production of ethanol. Specifically, power production devices and methods of generating power from dry corn fractionation products for the production of ethanol.
Type:
Grant
Filed:
November 22, 2006
Date of Patent:
June 10, 2014
Assignee:
MOR Technology, LLC
Inventors:
Kenneth E. DeLine, Daniel L. Claycamp, Daniel Fetherston
Abstract: The present invention concerns compositions and methods of extracting infectious pathogens from a volume of blood. In one embodiment, the method includes the steps of creating a fibrin aggregate confining the pathogens and introducing a fibrin lysis reagent to expose the pathogens for analysis. The present invention also concerns materials and methods for removing aurintricarboxylic acid (ATA) from a sample.
Abstract: Novel strains and methods for their use are provided. Particularly, foods and other oral products or treatments containing sporulation-deficient Brevibacillus strain when administered to a subject can inhibit or reduce the number of pathogens in the subject and improve the health of the subject.
Abstract: Two RNases (ranpirnase and the second embodiment disclosed in U.S. Pat. No. 5,728,805) are tested against human papillomavirus infections. QRT-PCR assays indicate that the RNases have anti-viral activity against type 11 HPV.
Abstract: The present invention concerns compositions and methods of extracting infectious pathogens from a volume of blood. In one embodiment, the method includes the steps of creating a fibrin aggregate confining the pathogens and introducing a fibrin lysis reagent to expose the pathogens for analysis. The present invention also concerns materials and methods for removing aurintricarboxylic acid (ATA) from a sample.
Abstract: The present invention concerns compositions and methods of extracting infectious pathogens from a volume of blood. In one embodiment, the method includes the steps of creating a fibrin aggregate confining the pathogens and introducing a fibrin lysis reagent to expose the pathogens for analysis. The present invention also concerns materials and methods for removing aurintricarboxylic acid (ATA) from a sample.
Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an iduronate-2-sulfatase (I2S) protein, salt, and a polysorbate surfactant for the treatment of Hunters Syndrome.
Type:
Grant
Filed:
June 25, 2011
Date of Patent:
October 1, 2013
Assignee:
Shire Human Genetic Therapies, Inc.
Inventors:
Gaozhong Zhu, Kris Lowe, Zahra Shahrokh, James Christian, Richard Fahmer, Jing Pan, Teresa Leah Wright, Pericles Calias
Abstract: A method for manufacturing a linear-chain beta-1,3-glucan is disclosed that comprises polymerizing glucose-1-phosphate serving as a substrate by contacting the glucose-1-phosphate with a beta-1,3-glucan phosphorylase derived from a species in the genus Ochromonas. A laminarioligosaccharide may be added to serve as a primer. A linear-chain beta-1,3-glucan having a degree of polymerization between about 30 to 70 is also disclosed.